Immunotherapy Approaches in HPV-Associated Head and Neck Cancer.

The trial has completed accrual; a recent press release from Bristol Myers Squibb expressed that the study did not reach its primary endpoints including OS and PFS although a positive trend was noted in OS in a subgroup of patients whose tumors expressed PD-L1 with a CPS ≥ 20 [ 47 ].

also in 11,005 other papers